Todd Foley - 08 Jan 2026 Form 3 Insider Report for Aktis Oncology, Inc. (AKTS)

Role: Director, 10%+ Owner
Signature: /s/ Todd Foley
Issuer symbol: AKTS
Transactions as of: 08 Jan 2026
Net transactions value: $0
Form type: 3
Filing time: 08 Jan 2026, 21:03:35 UTC
Previous filing: 12 Jun 2023
Next filing: 14 Jan 2026
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Foley Todd	Director, 10%+ Owner	C/O MPM BIOIMPACT LLC, 399 BOYLSTON STREET, SUITE 1100, BOSTON	/s/ Todd Foley	08 Jan 2026	0001473930

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	AKTS	Series Seed Redeemable Convertible Preferred Stock							08 Jan 2026	Common Stock	597,391	$0.000000	See Footnote	F1, F2, F3
holding	AKTS	Series A Redeemable Convertible Preferred Stock							08 Jan 2026	Common Stock	2,688,270	$0.000000	See Footnote	F1, F2, F4
holding	AKTS	Series B Redeemable Convertible Preferred Stock							08 Jan 2026	Common Stock	716,872	$0.000000	See Footnote	F1, F2, F5
holding	AKTS	Stock Option (Right to Buy)							08 Jan 2026	Common Stock	37,866	$18.00	Direct	F6

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each share of Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock is convertible into shares of the Issuer's Common Stock on a 3.8044-for-1 basis. Upon the closing of the Issuer's initial public offering, all shares of Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock will convert into shares of Common Stock of the Issuer. The Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock have no expiration date.
F2	The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.
F3	The shares are held as follows: 556,810 by MPM BioVentures 2018, L.P. ("BV 2018"), 29,593 by MPM BioVentures 2018 (B), L.P. ("BV 2018(B)") and 10,988 by MPM Asset Management Investors BV2018 LLC ("AM BV2018"). MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC ("BV2018 LLC") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. The Reporting Person is a managing director of BV 2018 LLC.
F4	The shares are held as follows: 2,505,648 by BV 2018, 133,170 by BV 2018(B) and 49,452 by AM BV2018.
F5	The shares are held as follows: 668,173 by BV 2018, 35,512 by BV 2018(B) and 13,187 by AM BV2018.
F6	1/36th of the original number of shares subject to the option shall vest in monthly installments from January 8, 2026, subject to the Reporting Person's continuous service through each vesting date, inclusive.